Comparative Pharmacology
Head-to-head clinical analysis: APHTHASOL versus CAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APHTHASOL versus CAPEX.
APHTHASOL vs CAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aphthasol (amlexanox) is an anti-inflammatory agent that inhibits the formation and release of inflammatory mediators such as histamine and leukotrienes from mast cells, neutrophils, and other inflammatory cells. It also inhibits the activation of eosinophils and neutrophils, and reduces cytokine production, thereby suppressing the immune response involved in aphthous ulcer formation.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Adults: 5 mg orally three times daily for 5 days.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life is 1.5 to 2.5 hours. This short half-life supports multiple daily dosing for local therapeutic effect with minimal systemic accumulation.
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Renal excretion of unchanged drug and metabolites accounts for approximately 50-60% of the administered dose, with the remainder eliminated via biliary/fecal routes as metabolites and unchanged drug. Biliary excretion constitutes about 20-30%.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid